Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.33 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484039 | 0.93 | MTHFD2 (0.30) | MTHFD2 | |
| SCHEMBL24469881 | 0.91 | MTHFD2 (0.33) | P2RX7MTHFD2AVPR2AVPR1AKCNK3 | |
| SCHEMBL24469803 | 0.91 | NR1H2 (0.32) | P2RX7MTHFD2NR1H2NR1H3KCNK3 | |
| SCHEMBL24483898 | 0.90 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL26841980 | 0.89 | NR1H2 (0.33) | P2RX7MTHFD2NR1H2NR1H3KCNK3 | |
| SCHEMBL26841989 | 0.89 | NR1H2 (0.33) | P2RX7MTHFD2NR1H2NR1H3KCNK3 | |
| SCHEMBL24484050 | 0.89 | — | — | |
| SCHEMBL24483968 | 0.88 | NR1H2 (0.32) | P2RX7NR1H2NR1H3KCNK3 | |
| SCHEMBL24483821 | 0.88 | SCD (0.34) | P2RX7NR1H2NR1H3TP53 | |
| SCHEMBL24469859 | 0.88 | NR1H2 (0.34) | P2RX7MTHFD2NR1H2NR1H3KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX7 2406/4885MTHFD2 2383/4885NR1H2 477/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | P2RX7 2406/4885MTHFD2 2383/4885NR1H2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.